All News
Brilliant summary slide re:RA and PsA during an as-always entertaiing by Dr. Seo
Personal opinion?
-Persolimab will have narrow role & may cause CA
-BIME will be 2nd line for PsA
-Tyk-2's will be the next big thing
Also... time for H2H trials!!!
@RheumNow #ACR23 https://t.co/lDvsK8h7WH
Mike Putman EBRheum ( View Tweet)
#ACR23 YiR! Dr. P. Seo reviews 2023 novel therapeutic agents we may see on the horizon. @RheumNow https://t.co/d0V41jAh3G
Dr. Rachel Tate ( View Tweet)
Considering a career in Rheumatology?
Dr. Philip Seo shares latest data from Lancet Rheumatology on the burden of disease of MSK disorders
👉123%⬆️since 1990
👉⬆️by 50% in 2050!
Year in Review
#ACR23 @RheumNow @rheumarhyme @doktora_ging @PhRheumaJr https://t.co/iypUn9MTu6
sheila ( View Tweet)
Can colchine reduce need for knee/hip replacement? Dr Seo #YearReview #ACR23 @RheumNow https://t.co/EpMl2nDZQ6
TheDaoIndex KDAO2011 ( View Tweet)
NORD-STAR study
RA pts treated with MTX + certolizumab, abatacept, tocilizumab or triple therapy
Certolizumab and Abatacept share 1st place!
Toci 2nd
Should we place abatacept higher on the RA tx hierarchy?
@RheumNow #ACR23 https://t.co/QvyzkLOcmX
Robert B Chao, MD ( View Tweet)
Still disgesting NORD-STAR, kind of surprised by the TCZ response?
As per usual, ABA is probably an under-used option for RA
@RheumNow #ACR23 https://t.co/QKyeuhqnXB
Mike Putman EBRheum ( View Tweet)
Novel therapeutics for #inflammatoryArthritis #YearInReciew #ACR23 @RheumNow https://t.co/9flVkGRn8v
TheDaoIndex KDAO2011 ( View Tweet)
Novel therapeutics for #SLE and #SSc #ACR23 @RheumNow https://t.co/yBSaTpNZLN
TheDaoIndex KDAO2011 ( View Tweet)
#ACR23 I’ll be at the Poster Hall tomorrow 12/11/23 between 9-11 am to present our work on clinical and biomarkers to exclude imminent autoimmune connective tissue disease #lupus #sjogren in people with ANA+. Do come and say hi 👋🏼 😃 https://t.co/wzRB7QXZsF
Md Yuzaiful Md Yusof ( View Tweet)
Takeaways from #ACR23 #ReviewCourse session on Systemic Sclerosis Screening for Organ Involvement - Dr. Francesco Boin
1. Always approach SSc as a systemic disease (see slide). Survival is determined by subset (limited vs diffuse) and organ manifestations.
2. Autoantibodies… https://t.co/TmrPqLJYzD https://t.co/ajHDVpUbhO
Paul Sufka, MD psufka ( View Tweet)
Axial PsA or AS? #ACR23 Abs #0492 finds age > 45 at LBP onset, female sex, higher frequency of PsO, and shorter time to dx may be better predictors of axial PsA. https://t.co/3sEj8NxtzP @rheumnow https://t.co/nV7NHk7WtD
Dr. Rachel Tate ( View Tweet)
Deucravacitinib tx found to have comparable effects on PsA disease activity and PROs after 16 weeks in both male and female patients. #ACR23 Abs 0485 https://t.co/w36rX3B77K @rheumnow https://t.co/q41ioJDMML
Dr. Rachel Tate ( View Tweet)
Racial/ethnic minority PsA pts less likely to be diagnosed w/in 12 mos from symptom onset (50% vs 71%; P < 0.001) and more frequently uninsured (8% vs. 1%; P < 0.001) compared to white pts. #ACR23 Abs #0490 https://t.co/MKO9hblGYT @rheumnow https://t.co/K8GgkhHOqw
Dr. Rachel Tate ( View Tweet)
In bDMARD-IR AS patients, UPA led to numerically greater improvements vs PBO in physical activity as measured by a wearable device over 14 wks, especially in sedentary patients. #ACR23 Abs #0530 https://t.co/6Me2XctK6D @rheumnow https://t.co/c6E2GfAGt4
Dr. Rachel Tate ( View Tweet)
Large Chicago study Abs #0535 at #ACR23 biologic tx prescribed more often for males, Non-Hispanic Blacks and Latinx in AS. Low SES, measured by SDI, and insurance status did not affect if pt received bDMARD. https://t.co/MdDuNPMCC9 @rheumnow https://t.co/Oa9aC3rbb0
Dr. Rachel Tate ( View Tweet)
Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/0RDwTdzhwS
Dr. John Cush RheumNow ( View Tweet)
Following on from the #ACR23 keynote, a deeper dive on how AI might actually help clinical rheumatologists in real life, from clinical rheumatologist @DrCMcMaster @DT4Health et al in @ACR_Journals:
https://t.co/dQJzTwScy0
@RheumNow
David Liew drdavidliew ( View Tweet)
#ACR23 Abs #0505 found use of IL-17 inhibitors and oral DMARD alone were associated with a decreased likelihood of achieving MDA in PsA. Small sample size, but interesting finding nonetheless. https://t.co/CAZGykwxRT @rheumnow https://t.co/8ptF8aTIFu
Dr. Rachel Tate ( View Tweet)
💡RP is a heterogeneous disease.
💡Think VEXAS in RP with MDS.
💡Think MAGIC if oral/genital ulcers.
💡Pts are experts on their own disease! Listen and acknowledge their symptoms. Shout out to Dr @maferradastrong
#ACR23 #ImNotYellingImColombian🇨🇴
@ACRheum @RheumNow https://t.co/nTZ96pJh09
Adela Castro AdelaCastro222 ( View Tweet)
💡Screen pts with Ssc for ILD with HRCT at diagnosis.
💡“MCTD” may meet criteria for Ssc dont look away at the positive U1RNP!
💡Kidney biopsy in SRC =Time is of the essence.
💡Cardiac involvement is 2nd cause of mortality screen with echo annually. @fboinMD #ACR23 @RheumNow https://t.co/yp3yjqqeQv
Adela Castro AdelaCastro222 ( View Tweet)